Separation of Low- Versus High-grade Crohn's Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker Analysis.


Journal

Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676

Informations de publication

Date de publication:
13 Mar 2020
Historique:
pubmed: 17 8 2019
medline: 5 1 2021
entrez: 17 8 2019
Statut: ppublish

Résumé

Crohn's disease-associated small bowel carcinoma is a rare event, usually reported to have a severe prognosis. However, in previous investigations we have found a minority of cases displaying a relatively favourable behaviour, thus outlining the need to improve the histopathological prediction of Crohn's disease-associated small bowel carcinoma prognosis. As in recent studies on colorectal cancer, a substantial improvement in prognostic evaluations has been provided by the histological analysis of the tumour invasive front; we therefore systematically analysed the tumour budding and poorly differentiated clusters in the invasive front of 47 Crohn's disease-associated small bowel carcinomas collected through the Small Bowel Cancer Italian Consortium. Both tumour budding and poorly differentiated cluster analyses proved highly effective in prognostic evaluation of Crohn's disease-associated small bowel carcinomas. In addition, they retained prognostic value when combined with two other parameters, i.e. glandular histology and stage I/II, both known to predict a relatively favourable small bowel carcinoma behaviour. In particular, association of tumour budding and poorly differentiated clusters in a combined invasive front score allowed identification of a minor subset of cancers [12/47, 25%] characterised by combined invasive front low grade coupled with a glandular histology and a low stage [I or II] and showing no cancer-related death during a median follow-up of 73.5 months. The improved distinction of lower- from higher-grade Crohn's disease-associated small bowel carcinomas provided by invasive front analysis should be of potential help in choosing appropriate therapy for these rare and frequently ominous neoplasms.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Crohn's disease-associated small bowel carcinoma is a rare event, usually reported to have a severe prognosis. However, in previous investigations we have found a minority of cases displaying a relatively favourable behaviour, thus outlining the need to improve the histopathological prediction of Crohn's disease-associated small bowel carcinoma prognosis.
METHODS METHODS
As in recent studies on colorectal cancer, a substantial improvement in prognostic evaluations has been provided by the histological analysis of the tumour invasive front; we therefore systematically analysed the tumour budding and poorly differentiated clusters in the invasive front of 47 Crohn's disease-associated small bowel carcinomas collected through the Small Bowel Cancer Italian Consortium.
RESULTS RESULTS
Both tumour budding and poorly differentiated cluster analyses proved highly effective in prognostic evaluation of Crohn's disease-associated small bowel carcinomas. In addition, they retained prognostic value when combined with two other parameters, i.e. glandular histology and stage I/II, both known to predict a relatively favourable small bowel carcinoma behaviour. In particular, association of tumour budding and poorly differentiated clusters in a combined invasive front score allowed identification of a minor subset of cancers [12/47, 25%] characterised by combined invasive front low grade coupled with a glandular histology and a low stage [I or II] and showing no cancer-related death during a median follow-up of 73.5 months.
CONCLUSIONS CONCLUSIONS
The improved distinction of lower- from higher-grade Crohn's disease-associated small bowel carcinomas provided by invasive front analysis should be of potential help in choosing appropriate therapy for these rare and frequently ominous neoplasms.

Identifiants

pubmed: 31418007
pii: 5550404
doi: 10.1093/ecco-jcc/jjz140
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

295-302

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Giovanni Arpa (G)

Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia, and Fondazione IRCCS San Matteo Hospital, Pavia, Italy.

Federica Grillo (F)

Pathology Unit, Department of Surgical and Diagnostic Sciences, University Hospital and Ospedale Policlinico San Martino IRCCS, Genova, Italy.

Paolo Giuffrida (P)

Department of Internal Medicine, Fondazione IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy.

Gabriella Nesi (G)

Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.

Catherine Klersy (C)

Service of Clinical Epidemiology & Biometry, Fondazione IRCCS San Matteo Hospital, Pavia, Italy.

Claudia Mescoli (C)

Pathology Unit, Department of Medicine, University of Padua, Padua, Italy.

Marco Vincenzo Lenti (MV)

Department of Internal Medicine, Fondazione IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy.

Gessica Lobascio (G)

Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia, and Fondazione IRCCS San Matteo Hospital, Pavia, Italy.

Michele Martino (M)

Department of Internal Medicine, Fondazione IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy.

Giovanni Latella (G)

Gastroenterology Unit, Department of Life and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Deborah Malvi (D)

Department of Experimental, Diagnostic and Specialty Medicine [DIMES], Institute of Oncology and Transplant Pathology, University of Bologna, Policlinico St Orsola-Malpighi Hospital, Bologna, Italy.

Maria Cristina Macciomei (MC)

Pathology Unit, San Camillo-Forlanini Hospital, Rome, Italy.

Paolo Fociani (P)

Unit of Pathology, Luigi Sacco University Hospital, Milan, Italy.

Vincenzo Villanacci (V)

Pathology Section, Spedali Civili Hospital, Brescia, Italy.

Aroldo Rizzo (A)

Pathology Unit, Cervello Hospital, Palermo, Italy.

Stefano Ferrero (S)

Division of Pathology, Department of Biomedical, Surgical and Dental Sciences, University of Milan, and Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Fausto Sessa (F)

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Augusto Orlandi (A)

Department of Biopathology and Image Diagnostics, University of Tor Vergata, Rome, Italy.

Giovanni Monteleone (G)

Department of Systems Medicine, University of Tor Vergata, Rome, Italy.

Livia Biancone (L)

Department of Systems Medicine, University of Tor Vergata, Rome, Italy.

Laura Cantoro (L)

Gastroenterologia Aziendale USL Umbria, Perugia, Italy.

Francesco Tonelli (F)

Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.

Antonio Ciardi (A)

Department of Radiological, Oncological, Pathological Sciences, Umberto I Hospital, La Sapienza University, Rome, Italy.

Gilberto Poggioli (G)

Surgery of the Alimentary Tract, Department of Medical and Surgical Sciences, Sant'Orsola - Malpighi Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy.

Fernando Rizzello (F)

Intestinal Chronic Bowel Disease Unit, Department of Medical and Surgical Sciences, Sant'Orsola Malpighi Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy.

Sandro Ardizzone (S)

Gastroenterology, Luigi Sacco University Hospital, Milan, Italy.

Gianluca Sampietro (G)

IBD Surgery, Luigi Sacco University Hospital, Milan, Italy.

Gaspare Solina (G)

General Surgery, Cervello Hospital, Palermo, Italy.

Barbara Oreggia (B)

General Surgery Unit, Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Milan, Italy.

Claudio Papi (C)

IBD, San Filippo Neri Hospital, Rome, Italy.

Renata D'Incà (R)

Gastroenterology Section, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.

Maurizio Vecchi (M)

Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, and Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

Flavio Caprioli (F)

Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, and Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

Roberto Caronna (R)

Surgical Sciences, Umberto I Hospital, La Sapienza University, Rome, Italy.

Antonietta D'Errico (A)

Department of Experimental, Diagnostic and Specialty Medicine [DIMES], Institute of Oncology and Transplant Pathology, University of Bologna, Policlinico St Orsola-Malpighi Hospital, Bologna, Italy.

Roberto Fiocca (R)

Pathology Unit, Department of Surgical and Diagnostic Sciences, University Hospital and Ospedale Policlinico San Martino IRCCS, Genova, Italy.

Massimo Rugge (M)

Pathology Unit, Department of Medicine, University of Padua, Padua, Italy.

Gino Roberto Corazza (GR)

Department of Internal Medicine, Fondazione IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy.

Ombretta Luinetti (O)

Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia, and Fondazione IRCCS San Matteo Hospital, Pavia, Italy.

Marco Paulli (M)

Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia, and Fondazione IRCCS San Matteo Hospital, Pavia, Italy.

Enrico Solcia (E)

Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia, and Fondazione IRCCS San Matteo Hospital, Pavia, Italy.

Antonio Di Sabatino (A)

Department of Internal Medicine, Fondazione IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy.

Alessandro Vanoli (A)

Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia, and Fondazione IRCCS San Matteo Hospital, Pavia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH